Stocks and Investing
Stocks and Investing
Mon, May 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Berens Maintained (VIRX) at Buy and Held Target at $11 on, May 8th, 2023
Andrew Berens of SVB Securities, Maintained "Viracta Therapeutics, Inc." (VIRX) at Buy and Held Target at $11 on, May 8th, 2023.
Andrew has made no other calls on VIRX in the last 4 months.
There are 3 other peers that have a rating on VIRX. Out of the 3 peers that are also analyzing VIRX, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Andrew
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $16 on, Monday, March 27th, 2023
- Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $35 on, Tuesday, March 14th, 2023
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $8 on, Tuesday, March 14th, 2023
Contributing Sources